IRIS
DRAGONI, FILIPPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.290
NA - Nord America 1.973
AS - Asia 1.005
SA - Sud America 212
AF - Africa 53
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.552
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.936
RU - Federazione Russa 626
IT - Italia 418
IE - Irlanda 353
GB - Regno Unito 343
SG - Singapore 304
CN - Cina 230
BR - Brasile 193
DE - Germania 134
SE - Svezia 132
HK - Hong Kong 124
FR - Francia 101
IN - India 82
VN - Vietnam 59
FI - Finlandia 52
PK - Pakistan 45
KR - Corea 42
ES - Italia 25
CA - Canada 22
UA - Ucraina 20
JP - Giappone 19
PL - Polonia 19
BD - Bangladesh 17
AU - Australia 16
IR - Iran 14
TR - Turchia 12
AT - Austria 11
MX - Messico 11
BE - Belgio 10
ZA - Sudafrica 10
NG - Nigeria 8
EG - Egitto 7
IQ - Iraq 7
MA - Marocco 7
NL - Olanda 7
TW - Taiwan 7
AR - Argentina 6
CZ - Repubblica Ceca 6
GH - Ghana 6
GR - Grecia 6
DK - Danimarca 5
DZ - Algeria 5
EC - Ecuador 5
ID - Indonesia 5
MY - Malesia 5
NP - Nepal 5
CI - Costa d'Avorio 4
CY - Cipro 4
TH - Thailandia 4
AZ - Azerbaigian 3
LV - Lettonia 3
NO - Norvegia 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
KE - Kenya 2
LK - Sri Lanka 2
LT - Lituania 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
RO - Romania 2
UZ - Uzbekistan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EU - Europa 1
GY - Guiana 1
HN - Honduras 1
IL - Israele 1
IM - Isola di Man 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
MN - Mongolia 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TN - Tunisia 1
VE - Venezuela 1
Totale 5.552
Salva come PNG Salva come JPEG
Città #
Dublin 350
Southend 278
Dallas 273
Chandler 203
Singapore 178
Moscow 167
Santa Clara 147
Ashburn 145
Fairfield 144
Hong Kong 116
Siena 107
Beijing 79
Seattle 63
New York 62
Munich 59
Houston 51
Woodbridge 50
Princeton 48
Cambridge 47
Los Angeles 45
Wilmington 37
Seoul 36
Hefei 34
Milan 33
Helsinki 29
Ann Arbor 26
Rome 26
Bengaluru 21
São Paulo 20
Málaga 18
Dong Ket 17
Boardman 16
Jacksonville 16
Redondo Beach 16
Shanghai 16
Florence 15
Portsmouth 14
Tokyo 14
Ho Chi Minh City 13
Lauterbourg 13
Warsaw 13
Atlanta 12
Frankfurt am Main 12
London 12
San Diego 12
Turku 12
Buffalo 11
Chennai 11
San Mateo 11
The Dalles 11
Brussels 10
Düsseldorf 10
Nuremberg 10
Brisbane 9
Dearborn 9
Fremont 9
Hanoi 9
Multan 9
San Francisco 9
Brescia 8
Brooklyn 8
Chicago 8
Islamabad 8
Lappeenranta 8
Mumbai 8
Perugia 8
Poplar 8
Toronto 8
Denver 7
Divinópolis 7
Karachi 7
Mexico City 7
Montreal 7
Orem 7
Rawalpindi 7
Roccagorga 7
São José do Rio Preto 7
Belo Horizonte 6
Council Bluffs 6
Guangzhou 6
Jaipur 6
Johannesburg 6
Lahore 6
Naples 6
Phoenix 6
Vienna 6
Cairo 5
El Hadjira 5
Lagos 5
Lograto 5
North Bergen 5
Redwood City 5
Rio de Janeiro 5
Stockholm 5
Abidjan 4
Accra 4
Andover 4
Brasília 4
Brno 4
Cagliari 4
Totale 3.496
Salva come PNG Salva come JPEG
Nome #
Antiviral drug development for treatment of acute and chronic viral infections 493
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 280
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 277
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 259
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 234
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 228
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 218
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 217
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 209
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 179
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 167
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 165
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 159
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 158
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 157
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 154
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 150
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 143
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 143
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 127
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 123
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 120
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 119
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 119
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 119
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 114
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected 109
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 108
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 106
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 105
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 95
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 95
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 89
Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia 85
null 32
null 14
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 10
Totale 5.679
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021290 0 0 0 0 0 43 37 52 34 49 28 47
2021/2022595 28 59 46 66 40 37 44 36 38 43 57 101
2022/2023652 41 89 72 55 54 121 38 50 39 34 29 30
2023/2024601 20 21 54 37 4 165 197 18 0 11 31 43
2024/20251.287 36 43 192 67 127 98 52 100 111 96 120 245
2025/20261.831 180 313 250 382 624 82 0 0 0 0 0 0
Totale 5.679